Acasti Pharma Unaware of Any Material Change
Acasti Pharma, Inc. - Class A (ACST)
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: GlobeNewswire
LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG. Forward Looking Statements Statements in this press release that are not statements of historical or current fact constitute “forwar
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial [Yahoo! Finance]Yahoo! Finance
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON TrialGlobeNewswire
ACST
Earnings
- 2/12/24 - Beat
ACST
Sec Filings
- 4/9/24 - Form SC
- 4/1/24 - Form 8-K
- 2/13/24 - Form SC
- ACST's page on the SEC website